DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/8vr9nj/medipoint) has announced the addition of the "MediPoint: Coronary Stents - Global Analysis and Market Forecasts" report to their offering.
Coronary Stent Sales by Region
Coronary stents can be used for a wide range of indications in coronary artery disease (CAD), including de novo lesions, small-vessel disease (SVD), bifurcation lesions, and tortuous and narrow lesions. Coronary stents can improve the clinical outcomes for all of these indications as well as quality of life for patients suffering from this debilitating disease.
In 2013, sales of DES and BMS in the 10MM were $4.89 billion. The authors estimates the 2014 sales of DES and BMS in the 10MM to be $4.99 billion. By 2020, sales of coronary stents, including bare metal and drug-eluting stents, will grow to $5.62 billion, at a Compound Annual Growth Rate (CAGR) of 2.0%. To date, BAS have not received regulatory approval and been launched in the US, Japanese, and Chinese markets, but are expected to enter these markets in the near future.
Of the 10MM covered in the report, the US currently has and will continue to have the largest share in the coronary stents market. Together, the US, the 5EU countries, and Japan will account for 64% of the coronary stents market for BMS and DES in 2020. Collectively, the 5EU countries are forecast to have only 10% market share in the future. Among the emerging markets, China has captured significant market share, which is expected to increase in the future. The emerging markets, including Brazil, China, and India, are expected to demonstrate the greatest growth in the market over the forecast period and will serve as an outlet of expansion for stent manufacturers to increase their global presence.
The key drivers for the coronary stents market during the forecast period are:
- The rising prevalence of CAD in the major markets covered in this report
- The need for effective therapies that reduce the risk of complications, such as restenosis (re-narrowing of the coronary artery), chronic inflammation, and thrombosis, and the need for target lesion revascularization (TLR) associated with bare metal and drug-eluting stenting
- The cost savings for healthcare payers resulting from the reduced need for repeat revascularization procedures and prolonged dual antiplatelet therapy
- Reducing the need for stent-in-stent procedures and improving the technical feasibility of future interventions
- Innovations in stent technology with regard to the platform, material, and coating
- The increase in patients' disposable income and government insurance coverage in the emerging markets, such as China and India
- The approval and launch of BAS, such as the Absorb BVS, in the US, Japan, and China
Key Topics Covered:
1 Tables & Figures
2 Introduction
3 Industry Overview
4 Unmet Needs
5 Market Opportunity Analysis
6 Market Drivers, Barriers, and Substitutes
7 Competitive Assessment
8 Pipeline Products
9 Clinical Trial Analysis
10 Current and Future Players
11 Market Outlook
12 Appendix
Companies Mentioned
- Abbott Vascular
- Alvimedica
- Amaranth Medical
- Arterial Remodeling Technologies
- B. Braun
- Balton
- Biosensors International
- Biotronik
- Blue Medical
- Boston Scientific Corporation
- C.R. Bard
- Cardionovum
- Elixir Medical Corporation
- Hexacath
- IRAMED
- JW Medical Systems
- Kyoto Medical Planning
- Lepu Medical Technology
- MIV Therapeutics
- Medtronic
- MicroPort Scientific Corporation
- Minvasys
- Opto Circuits
- OrbusNeich Medical
- REVA Medical
- Relisys Medical Devices
- STENTYS
- Sahajanand Medical Technologies
- Terumo Corporation
-
Translumina
For more information visit http://www.researchandmarkets.com/research/8vr9nj/medipoint
